Datadog Inc vs Zimmer Biomet Holdings Inc — how do they compare? Datadog Inc trades at $278.23 (market cap $98.31B), while Zimmer Biomet Holdings Inc trades at $89.52 (market cap $16.95B). The key difference: Datadog Inc is far larger — about 5.8× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DDOG | ZBH | |
|---|---|---|
Market Cap | $98.31B | $16.95B |
Volume | 2,936,660 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $288.15 | $103.98 |
52-Week Low | $102.62 | $79.58 |
Typical Hold Time | 76 Days | 89 Days |
Enterprise Value | $94.61B | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $271.34, down 2.48% on the day, but maintains a bullish technical outlook with strong support near $269. The company continues to deliver robust revenue growth, reaching $3.43B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with a consensus price target of $276.10, though high valuation multiples like a P/E of 547.6 signal premium pricing. Recent news highlights accelerating AI and enterprise customer expansion as key growth drivers.
The outlook for DDOG is favorable given its consistent earnings beats and strategic positioning in cloud observability and AI infrastructure. However, investors face risks from elevated valuations, negative net cash flow, and competitive pressures in the cloud software sector. The stock's proximity to its consensus target suggests limited near-term upside, making execution on growth initiatives critical for further appreciation.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →